Abstract:Ravindranath et all recently reported the results of treatment for 12 children with acute myeloid leukemia (AML) and Down syndrome (DS) using a Pediatric Oncology Group (POG) AML protocol with 4 to 6 courses of high-dose cytarabine (Am-C) as postremission therapy. According to the report, children with DS and AML were characterized by a young age at diagnosis (120 months in 10 of 12) and a high incidence of acute megakaryoblastic leukemia (M7, 5 of 12). It was also noteworthy that children with DS had a superior eventfree survival when compared with children without DS (EFS at 4 years; loo%, 28% f 6.2%). We recently treated nine children with AML and DS (Table I). All of them were diagnosed as having M7 using platelet-specific monoclonal antibodies and the platelet peroxidase (PPO) reaction on electron microscopy? Three children received induction chemotherapy with Ara-C (100 mg/m*/d on days 1 to 7) and daunorubicin (25 mg/m2/d on days 6 and 7). Consolidation chemotherapy was 6 courses of the same regimen. One patient has remained in continuous complete remission (CR) for more than 5 years, one relapsed during consolidation chemotherapy, and one died of heart failure. Remission induction chemotherapy for the subsequent 6 children consisted of daunorubicin (25 mg/mz/d on days 1 and 2), Ara-C (100 mg/mz/d for 7 consecutive days), and etoposide ( 1 50 mg/ m2/d on days 3,4 , and 5). Consolidation chemotherapy was 6 courses of the Same regimen. All six children achieved CR and have remained in CR for 4 to 48 months. In 5 of the 6 children, chemotherapy has already been terminated. During the same period, two non-DS children with M7 were treated with the Same protocol, but both of them failed to achieve CR. Our results as well as the POG study suggest that AML in DS is highly responsive to chemotherapy that includes daunorubicin and Ara-C. Although Ravindranath et al emphasized the contribution of intensive postremission therapy with highdose Ara-C to improvement of the EFS, our results suggest that a less intensive Am-C dose schedule with etoposide is also useful for the treatment of AML in children with DS. The French-American-British phenotypes were different between the two studies, because all 9 children had M7 in our study and only 5 of 12 children were classified as M7 in the POG study. For the diagnosis of M7, leukemic cells are identified as being of the megakaryocytic lineage by the PPO reaction on electron microscopy or by monoclonal or polyclonal platelet-specific antibodies.’ Because immunologic cell marker studies were only performed in 5 of 12 children, the incidence of M7 might have been underestimated in the POG study.

Research Advances on the Function of Non-structural Protein NS1 of Parvovirus

Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19

For better or worse: crosstalk of parvovirus and host DNA damage response

Progress of Influenza A Virus NS1 Protein Affect Host Cell's Apoptosis

RESEARCH ADVANCE ON NONSTRUCTRAL PROTEINS OF CORONAVIRUS

Research progress on the nonstructural protein 1 (NS1) of influenza a virus

The genetic evolution of canine parvovirus – A new perspective

Advance in the Research of the Nonstructural Protein NS2 of Hepatitis C Virus

Parvovirus B19 nonstructural protein-induced damage of cellular DNA and resultant apoptosis

Porcine Parvovirus Nonstructural Protein NS1 Activates NF-κB and It Involves TLR2 Signaling Pathway

Atraumatic rupture of the spleen in periarteritis nodosa.

Structures and implications of the nuclease domain of human parvovirus B19 NS1 protein

Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome.

NS1: A Key Protein in the “Game” Between Influenza A Virus and Host in Innate Immunity

Plötzliche bilaterale Visusminderung bei einem 14-jährigen Jungen

Crystal structure and nucleic acid binding mode of CPV NSP9: implications for viroplasm in Reovirales

Modeling of spread-spectrum clock generation system using simulink

Artifactual hypoglycemia in a patient with alcoholic hepatitis and hyperleukocytosis.

Secretory pathways and multiple functions of nonstructural protein 1 in flavivirus infection

Novel mutation N588 residue in the NS1 protein of feline parvovirus greatly augments viral replication

Research progress on the N protein of porcine reproductive and respiratory syndrome virus